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Abstract
Angiogenesis plays a critical role in tumor progression
in various cancers, including neuroblastoma. We have
previously shown that gastrin-releasing peptide (GRP)
stimulates neuroblastoma growth and that its cell
surface receptors, gastrin-releasing peptide receptors
(GRP-R), are overexpressed in advanced-stage human
neuroblastomas; however, the effects of GRP on angio-
genesis are not clearly elucidated. Interleukin (IL) 8, a
proinflammatory chemokine, plays an important role
during tumor angiogenesis. Ets transcription factors,
such as oncoproteins, cause tumor development and
are also known to induce IL-8 expression. In the present
study, we found an increased expression of Ets1 in
more undifferentiated human neuroblastomas. Stable
transfection of SK-N-SH human neuroblastoma cells
with Ets1 plasmid resulted in increased IL-8 luciferase
activity and IL-8 secretion into cell culture media.
Conversely, silencing of Ets1 resulted in a significant
decrease in IL-8 secretion in SK-N-SH cells. Moreover,
exogenous GRP treatment increased Ets1 (T38) phos-
phorylation and Ets1 nuclear accumulation, and en-
hanced Ets1 binding to its DNA consensus sequence,
resulting in the stimulation of IL-8 mRNA expression
and protein secretion. Our findings demonstrate that
GRP upregulates proangiogenic IL-8 expression in an
Ets1-dependent manner, suggesting a critical role of
this process during GRP-induced neuroblastoma
angiogenesis and metastasis.
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Introduction
Neuroblastoma is the most common extracranial solid
tumor in pediatric patients, and its clinical behavior is quite
variable, depending on its histopathological features. Angio-
genic factors are differentially expressed in neuroblastomas
in a pattern suggesting the promotion of a proangiogenic
phenotype in more undifferentiated aggressive tumors [1].
Recent studies implicate angiogenesis in the regulation of
neuroblastoma growth [2]. The vascularity of neuroblastomas
from patients with widely metastatic diseases is significantly
higher than that of tumors from patients with local or regional
diseases [2–4]. Hence, inhibition of angiogenesis could poten-
tially be a promising approach in the treatment of advanced-
stage neuroblastomas.
Neuroblastomas are known to produce and secrete various
peptides [5], including gastrin-releasing peptide (GRP) [6].
GRP, the mammalian equivalent of bombesin, is a neuro-
endocrine peptide that exerts many cellular functions, including
a growth-stimulatory effect on various cancer cell types. Re-
cently, we have shown that GRP and its cell surface receptor,
gastrin-releasing peptide receptor (GRP-R), are abundantly
expressed in human neuroblastomas [6]. Moreover, we have
found that clinically more aggressive undifferentiated tumors
express an increased level of GRP-R. GRP is produced and
secreted by human neuroblastoma cells, therefore acting as
an autocrine growth factor to stimulate its cellular growth [6].
However, the effects of GRP on neuroblastoma tumor angio-
genesis are unknown.
Tumor growth and metastasis depend on the ability of tumor
cells to induce angiogenesis, mediated by the release of
angiogenic factors that are secreted by tumor cells. Among
them, vascular endothelial growth factor (VEGF) [7] and inter-
leukin (IL) 8 [8] are the most potent angiogenic factors in
neuroblastoma. IL-8 is a member of the chemokine family that
has pleiotropic function, including roles in angiogenesis [9],
chemotaxis [10], and stem cell mobilization [11]. It is ex-
pressed by several tumor types, and its expression is regulated
primarily at the transcriptional level by transcription factors
such as AP-1 and NF-nB [12]. Recently, it has been reported
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that an IL-8 promoter contains three Ets-binding sites and
that myeloid ELF1-like factor, an Ets family transcription
factor, specifically binds to the IL-8 promoter in hematopoietic
cells [13]. IL-8 is expressed by a number of human malig-
nancies, and its expression correlates with the metastatic
potential of tumors. In particular, IL-8 has also been found to
be an important angiogenic factor in neuroblastoma [8].
The ets gene family encodes unique transcription regu-
lators that have a common Ets DNA–binding domain. So far,
approximately 30 members of the family have been identified
in mammals [14]. Ets1 expression levels strongly correlate
with the grade of invasiveness and metastasis in preinvasive
breast cancer [15,16] and in human colorectal carcinoma
[16]. Furthermore, Ets family transcriptional activators and
repressors are also involved in angiogenesis. Studies have
demonstrated that Ets transcription factors can regulate
multiple aspects of the malignant phenotype of many tumor
cells, in particular neoangiogenesis and extracellular matrix–
regulated cell proliferation, motility, and invasiveness [17].
In this study, we report that oncogenic Ets1 is over-
expressed in undifferentiated aggressive human neuro-
blastomas. GRP, which is expressed and secreted by
neuroblastoma cells, stimulates the transcriptional activity
of Ets1 by phosphorylation, inducing its translocation into
the nucleus and further increasing Ets1 binding to its DNA
consensus sequence. This process then results in IL-8mRNA
induction and protein secretion, suggesting a role for Ets1
during GRP-induced secretion of proangiogenic IL-8 in
neuroblastoma cells.
Materials and Methods
Cell Lines and Reagents
Neuroblastoma cell lines [SK-N-SH, IMR-32, BE(2)-C,
SK-N-MC, and SH-SY5Y] were purchased from the Ameri-
can Type Culture Collection (Manassas, VA). LAN-1 was a
gift from Dr. Robert C. Seeger (University of Southern Cali-
fornia, Los Angeles, CA). GRP peptide was from Bachem
(Torrance, CA) and was used at a concentration of 107 M
in all treatments. All reagents were from Sigma (St. Louis,
MO), unless otherwise specified.
Expression Constructs and Small Interfering RNA (siRNA)
IL-8 promoter luciferase plasmid was kindly provided
by Dr. Krach Michael (Institute of Pharmacology, Medical
School Hannover, Hanover, Germany). Constructs GAL4-
Ets1 and 5X GAL-Luc were gifts from Dr. V. Fafeur (Institute
de Biologie de Lille, Lille, France). Ets1 expression plasmid
(pSG5p51) was a gift from Dr. Runzhao Li (Laboratory of
Cancer Genomics, Medical University of South Carolina,
Charleston, SC). Ets1 siRNA vector (TranSilent Ets1 siRNA
vector) and its siRNA control vector were purchased from
Panomics (Redwood City, CA).
Cell Culture, Transfection, and Reporter Luciferase Assays
Cells were maintained in RPMI 1640 medium with
L-glutamine (Cellgro Mediatech, Inc., Herndon, VA) supple-
mented with 10% fetal bovine serum (FBS; Sigma). The cells
were maintained at 37jC in a humidified atmosphere of
95% air and 5% CO2. Cells were transfected with plasmid
DNA in 24-well plates using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
Reporter luciferase activity assays were performed with a
Dual-Luciferase Reporter Assay System (Promega Corpora-
tion, Madison, WI) after transfection for indicated times.
Immunohistochemistry
Immunohistochemical staining was performed according
to the protocol provided by DAKO EnVision+ System
(Dako Corporation, Carpinteria, CA). Formalin-fixed paraffin-
embedded sections (4 mm) were dewaxed in xylene and
rehydrated through graded alcohol to distilled water. The
sections were subjected to antigen retrieval by boiling in a
microwave for 20 minutes in a 0.01 M sodium citrate buffer
(pH 6.0). Endogenous peroxidase was blocked by treating
with blocking buffer for 5 minutes. Sections were blocked
with 5% bovine serum albumin in Tris-buffered saline (TBS)
buffer for 15 minutes before incubation with antibody. The
primary rabbit polyclonal antibody to Ets1 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) was applied at a dilution
of 1:500 and incubated overnight at 4jC. After incubation,
the slides were washed thrice with TBS for 5 minutes each.
Then the sections were incubated with secondary anti-
body conjugated with peroxidase for 30 minutes at room
temperature (RT). Antibody–antigen complexes were
detected by color changes on the addition of diaminobenzi-
dine. Counterstaining was performed with hematoxylin. Nega-
tive controls were obtained using normal serum, instead of the
primary antibody.
Immunofluorescent Staining
SK-N-SH cells were grown on coverslips in a 12-well plate,
fixed in 4% paraformaldehyde, and permeabilized in cold
methanol for 5 minutes. Cells were then incubated with
primary antibodies against Ets1 (1:500) for 1 hour at RT.
Cells were washed and treated with Rhodamin-conjugated
goat antirabbit secondary antibody (Molecular Probes,
Eugene, OR) for 1 hour at RTand then incubated with 4V,6V-
diamidino-2-phenylindole (DAPI) for 5 minutes at RT. Images
were obtained using a Nikon Eclipse E600 (Nikon Instru-
ments, Inc., Melville, NY).
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed with EMSA Gel-Shift Kit
(Panomics) according to the manufacturer’s protocol. Ets/
PU1 oligonucleotides (5V-AGTATGTCTAGACTGA-3V) were
labeled with biotin, mixed with nuclear proteins in a binding
buffer, and incubated with 2.5 mg of nuclear protein for
20 minutes at RT. Protein/DNA complexes were resolved
in 6% DNA Retardation Gels (Invitrogen) using 0.5 Tris-
borated–EDTA buffer.
Western Blot Analysis
Cells were cultured in tissue culture dishes for experi-
ments, unattached cells were removed by rinsing once
Ets1-Mediated GRP Stimulation of IL-8 Qiao et al. 185
Neoplasia . Vol. 9, No. 3, 2007
with phosphate-buffered solution, and attached cells were
scraped from culture dishes, pelleted, and resuspended in
cell lysis buffer (20mMTris–HCl pH 7.5, 150mMNaCl, 1mM
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyro-
phosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg/
ml leupeptin, and 1 mM PMSF added before use). Protein
concentrations were determined, and aliquots of each sam-
ple containing equal amounts of protein were diluted into a
sodium dodecyl sulfate sample buffer. Proteins were run on
4% to 12% NuPAGE Novex Bis–Tris Gels (Invitrogen),
transferred to polyvinylidene difluoride membranes, and
probed with antibodies. Bands were visualized by an en-
hanced chemiluminescent detection system ECL plus
according to the manufacturer’s instructions (Amersham,
Inc., Piscataway, NJ).
IL-8 Secretion Assay
Human neuroblastoma SK-N-SH cells were seeded at
1  105 cells/ml per well in 12-well plates and incubated in
RPMI 1640 medium with 10% FBS overnight. Cells were
then washed with media without FBS and treated with GRP
(107 M) for the indicated times. Cell culture supernatants
were collected after each experiment and centrifuged to
remove cells and debris. IL-8 in the supernatants of cultured
cells wasmeasured by enzyme-linked immunosorbent assay
(ELISA) in accordance with the manufacturer’s instructions
(Pierce Biotechnology, Inc., Rockford, IL).
Statistical Analysis
Each set of experiments was repeated at least thrice.
Values are given asmean ± SEM. Conditions were compared
using Student’s paired t test. One-way analysis of variance
on the ranks for repeated measures was performed for multi-
ple comparisons. Differences were considered significant
when P < .05.
Results
Increased Ets1 Expression in Poorly Differentiated
Human Neuroblastomas
The malignant behavior of neuroblastoma correlates
with the degree of tumor cell differentiation, where poorly
differentiated tumors are aggressive and often refractory
to treatment modalities [1]. A typical poorly differentiated
neuroblastoma is characterized by small cells with large
round nuclei and scant cytoplasm [18]. In contrast, well-
differentiated neuroblastomas (i.e., ganglioneuroma and
ganglioneuroblastoma) are heterogeneous, with large ma-
ture ganglion cells. In the present study, we analyzed 21
poorly differentiated and 16 well-differentiated human neuro-
blastomas by immunohistochemistry. Ets1 expression was
found in 18 of 21 poorly differentiated neuroblastomas, and
in 7 of 16 differentiated specimens (Figure 1A). Interestingly,
Ets1 protein was weakly expressed in both the nuclei and
the cytoplasm of Ets1-positive differentiated cells (Figure 1A,
panels a and c). In contrast, a strong Ets1 expression was
found in undifferentiated cell nuclei (brown stain; Figure 1A,
panels b and d ), indicating an inverse correlation between
cellular differentiation and Ets1 expression in human neuro-
blastomas. Additionally, Ets1 expression was also detected
in all six neuroblastoma cell lines examined at various
levels (data not shown).
Ets1 Upregulates IL-8 Transcription and Secretion
in Neuroblastoma Cells
To detect whether Ets1 contributes to angiogenesis in
neuroblastomas, SK-N-SH cells were transiently trans-
fected with Ets1 plasmid. The supernatants and cell lysates
were collected after transfection at various time points.
Ets1 protein expression was significantly increased at 24
and 48 hours after transfection, as confirmed by Western
blot analysis (Figure 2A). To determine the critical angiogenic
Figure 1. Ets1 expression in human neuroblastomas. (A) Paraffin-embedded human neuroblastoma sections were stained with an anti-Ets1 antibody visualized by
diaminobenzidine staining. Ets1 was strongly expressed in undifferentiated neuroblastoma cells (panels b and d), whereas weakly stained Ets1 was found in well-
differentiated neuroblastoma sections (panels a and c). Original magnification: 200 for panels (a) and (b); 400 for panels (c) and (d). (B) Ets1 protein was
expressed in 18 of 21 (86%) undifferentiated tumor sections, and in 7 of 16 (44%) differentiated tumor sections.
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molecules regulated by Ets1, a focused angiogenesis gene
array (SuperArray Bioscience, Frederick, MD) was per-
formed. Our array results showed that Ets1 overexpression
increased IL-8 mRNA expression (data not shown). To vali-
date this finding, we then performed IL-8 promoter reporter
assaysby cotransfectingSK-N-SHcellswith an IL-8 promoter
luciferase vector along with Ets1 plasmid. Ets1 increased
IL-8 promoter activity by four-fold at 8 hours and by approxi-
mately 15-fold at 16 hours when compared to control cells
transfected with an empty vector (Figure 2B), thus confirming
the gene array results. Furthermore, we measured IL-8 se-
cretion in culture supernatants by ELISA. Cells were trans-
fected with either Ets1 expression or control plasmid. Our
results showed that IL-8 secretion was significantly increased
at 24 hours and reached peak stimulation at 40 hours after
transfection in cells overexpressing Ets1 (Figure 2C).
GRP Induces Ets1 Phosphorylation and
Subcellular Localization
To investigate the effect of GRP on Ets1 activity, neuro-
blastoma cells were treated with GRP, and Ets1 phos-
phorylation was analyzed by Western blot analysis using a
specific antibody against phosphorylated Ets1 (pT38). Ets1
was rapidly phosphorylated at 5 minutes after GRP treat-
ment, and this persisted up to 60 minutes in SK-N-SH cells
(Figure 3A). A similar activation of Ets1 was noted after GRP
treatment in another neuroblastoma cell line, BE(2)-C. Phos-
phorylation of threonine-38 residue strongly increases the
transcriptional activity of Ets1 [19]. Furthermore, to determine
whether GRP treatment affects Ets1 intracellular localiza-
tion, we performed immunocytochemical analysis. The cells
grown on coverslips were fixed and stained with Ets1-specific
antibody; DAPI was used for nuclear staining. Our results
showed that GRP-treated cells demonstrate an intense nu-
clear accumulation of Ets1 within 1 hour when compared to
control cells with Ets1 noted in the cytoplasm (Figure 3B).
GRP Increases Ets1 Binding to Its DNA Consensus
Sequence and Ets1 Transactivation
So far, we have shown that GRP induces Ets1 phos-
phorylation and nuclear localization. We next assessed the
effect of GRP on Ets1 transcription factor activity. EMSA
was performed to examine the binding of nuclear Ets1 to
its DNA consensus sequence in vitro. Sequence-specific
binding of Ets1 to its biotin-labeled probe was observed.
Ets1 DNA–binding activity was increased with GRP treat-
ment (Figure 4A, lane 2); this was competitively blocked with
an unlabeled oligonucleotide (Figure 4A, lane 4). To deter-
mine whether GRP mediates Ets1 transactivation, SK-N-
SH cells were cotransfected with 5 GAL4-Luc with either
wild-type GAL4-Ets1 (1–244) or mutant GAL4-Ets1 (T38A)
plasmid. The cells were serum-starved for 24 hours and then
stimulated with GRP (107 M) for 24 hours. Ets1 transacti-
vation was enhanced by nearly 15-fold with GRP stimulation
in SK-N-SH cells (Figure 4B). In contrast, the mutant Ets1
(T38A) was devoid of Ets1 transactivation activity. These
Figure 2. Ets1 regulates IL-8 expression and secretion in SK-N-SH cells. (A) Cells were transfected with the Ets1 expression plasmid, and then Western blot
analysis was performed. (B) IL-8 promoter transcriptional activity was enhanced by cotransfection with Ets1 expression plasmid (mean ± SEM; *P < .05 vs control
vector). (C) IL-8 secretion into a culture supernatant was increased by Ets1 overexpression (mean ± SEM; *P < .05 vs control vector).
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data strongly suggest that the transactivation of Ets1 is
induced in response to GRP treatment in SK-N-SH human
neuroblastoma cells.
GRP Treatment Enhances IL-8 Luciferase Activity
and Ets1 Regulates GRP-Induced IL-8 Secretion
We have found that Ets1 is transactivated by GRP stimu-
lation and that Ets1 increases IL-8 promoter activity and
IL-8 secretion in neuroblastoma cells. Next, we further deter-
mined whether GRP stimulates IL-8 transcription and se-
cretion through the Ets1 transcription factor. SK-N-SH cells
were transfected with IL-8 luciferase plasmid and then
treated with GRP (107 M). GRP increased IL-8 promoter
activity to > 58% when compared to control at 24 hours
(Figure 5A). Moreover, GRP treatment also resulted in a
nearly three-fold increase in IL-8 secretion (Figure 5B). To
further validate the critical role of Ets1 during GRP-induced
IL-8 upregulation, we next transfected SK-N-SH cells with
Ets1 siRNA vector, which resulted in suppression of Ets1
protein levels by 50% (Figure 5C). Targeted Ets1 knockdown
significantly attenuated GRP-stimulated IL-8 secretion, when
compared to control cells transfected with control siRNA
vector (Figure 5D). Interestingly, Ets1 siRNA transfection
alone without GRP resulted in a significant decrease in IL-8
secretion (Figure 5D). Taken together, these results further
demonstrate that the Ets1 transcription factor plays an im-
portant role in regulating IL-8 transcription and secretion in
neuroblastoma cells.
Discussion
We have previously shown that GRP acts as a mitogenic
factor in neuroblastoma cells. Moreover, GRP-R over-
expression downregulates the expression of the tumor-
suppressor gene PTEN and promotes cell proliferation [20].
In this study, we found that GRP activates the Ets1 transcrip-
tion factor and causes Ets1 nuclear localization. Activated
Ets1 further induced proangiogenic factor IL-8 expression
and secretion. This process may be an important mechanism
contributing to aggressive tumor behavior as a result of en-
hanced angiogenesis in advanced-stage neuroblastomas.
Neuroblastoma tumor growth and metastasis depend on
nutrients supplied through neovascularization. A high vas-
cular index in neuroblastoma correlates with a poor overall
prognosis in patients [3]. IL-8 is an inflammatory cytokine and
potent angiogenic factor in vitro and in vivo. IL-8 induces
neovascular capillary formation in many solid tumors [21].
Figure 3. Ets1 phosphorylation and nuclear localization after GRP treatment.
(A) SK-N-SH cells were serum-starved overnight and then treated with GRP
(107 M). Induction of Ets1 phosphorylation was detected after GRP treat-
ment in both SK-N-SH and BE(2)-C cells by Western blot analysis. (B) For
immunofluorescent staining, SK-N-SH cells were seeded on coverslips and
serum-starved overnight. Ets1 protein was localized predominantly in the
nuclei at 1 hour (bottom panels) after GRP treatment (107 M) when compared
to controls (top panels). DAPI specifically stained for the DNA of nuclei.
Figure 4. GRP increases Ets1 DNA binding and transcription activity. (A) Nuclear protein was extracted from cells treated with GRP (107 M) for 4 hours. Nuclear
protein (2.5 g/lane) was added in binding reactions, and protein/DNA complexes were resolved in a 6% DNA retardation gel. (B) SK-N-SH cells were co-
transfected with 5 GAL4-Luc plus GAL4-Ets1 (WT) or GAL4-Ets1 (T38A) (dominant-negative mutant vector). Cells were treated with GRP (107 M) for 24 hours
after serum starvation. Ets luciferase activity was significantly increased after GRP treatment (data represent triplicate determinations; mean ± SEM; *P < .05 vs
control vector).
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In neuroblastoma cells, IL-8 is both expressed and secreted
[8]. In addition, the overexpression of MYCN, a critical
oncogene for neuroblastoma, has been shown to upregulate
IL-8 expression and secretion [22]. Hypoxia induces the ex-
pression of IL-8 in vascular endothelial cells through the
activation of NF-nB [23] and can be enhanced by the activa-
tion of the PI3-K/Akt and p38MAPK pathways [24]. Hoffmann
et al. [12] reported that c-Fos and Fos-related antigen-1, two
inducible components of AP-1, counteractively regulate the
endogenous IL-8 promoter in an IL-1–dependent manner.
Recently, it has been revealed that MEF, a member of Ets
family transcription factors, is a potent activator of IL-8
expression in hematopoietic cells [13]. Correspondingly, in
this study, we also found that Ets1 expression significantly
upregulates IL-8 expression and secretion in human neuro-
blastoma cells.
Ets1, a pro-oncogenic protein, is produced by a variety of
solid tumors, including neuroblastomas, epithelial tumors,
sarcomas, and astrocytomas. Ets1 expression is increased
in invasive advanced-stage tumors and is an indicator of poor
clinical prognosis [25]. Ets1 also promotes angiogenesis. It
has recently been shown that there is a significant correla-
tion between microvasculature and ets1 gene expression
levels in uterine endometrial cancers [26]. In another study,
constitutive Ets1 expression has been shown to stimulate
angiogenesis and to induce an invasive phenotype [27].
Our current study demonstrated that Ets1 expression also
correlates with tumor cellular differentiation, where in-
creased expression of Ets1 protein was detected in more
undifferentiated human neuroblastomas when compared to
Ets1 protein levels in well-differentiated tumors with mature
ganglion cells. However, a variable expression of Ets1 pro-
tein was noted in six human neuroblastoma cell lines irre-
spective of their histologic features (data not shown). More
importantly, overexpression of Ets1 upregulated IL-8 tran-
scription and secretion in neuroblastoma cells, strongly sug-
gesting a correlation of Ets1 expression with angiogenesis
in human neuroblastomas.
In SK-N-SH cells, we found that GRP increased the
phosphorylation of Ets1 transcription factor, induced Ets1
nuclear localization, and increased Ets1 DNA–binding ac-
tivity. Certainly, GRP-mediated activation of transcription
factors is not limited to Ets1 alone. Bombesin, an analog of
GRP, which acts as a mitogen, is known to induce the ex-
pression of the early response genes c-fos and c-jun, and
also activates transcription factor Elk1 in prostate cancer cell
lines [28]. In non–small cell lung cancer cells, GRP pro-
motes cell proliferation through transactivation of EGF re-
ceptor and induction of its downstream MAPK pathway [29].
Previously, we have demonstrated the role of GRP as an
Figure 5. GRP increases IL-8 luciferase activity, and Ets1 regulates GRP-induced IL-8 secretion in SK-N-SH cells. (A) For IL-8 promoter activity assays, cells were
seeded in 24-well plates, transfected with IL-8 luciferase plasmid DNA, and then treated with GRP (107 M). (B) For IL-8 secretion assay, cells in 12-well plates
(1  105 cells/well) were treated with GRP (107 M) for 24 hours. The culture supernatants were collected, and IL-8 in the culture supernatant was measured by
ELISA (data represent triplicate determinations; mean ± SEM; *P < .05 vs control). (C) Ets1 siRNA transfection yielded a significantly decreased Ets1 protein
expression by Western blot analysis. (D) Ets1 knockdown using siRNA significantly decreased IL-8 secretion. In addition, GRP-stimulated increase in IL-8
secretion was markedly attenuated in SK-N-SH cells transfected with Ets1 siRNA vector when compared to control cells transfected with control siRNA vector
(mean ± SEM; *P < .05 vs control siRNA vector; yP < .05 vs no GRP). All data represent triplicate determinations.
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autocrine growth factor for neuroblastoma cells [6]. There-
fore, our current findings suggest that the mitogenic action
of GRP may, in part, be mediated through the activation of
the proangiogenic Ets1 transcription factor.
Moreover, our present study showed thatGRPmoderately
upregulates the proangiogenic factor IL-8 both at the tran-
scriptional level and on protein secretion. Similarly, Levine
et al. [30] reported that bombesin stimulation of GRP-R
resulted in the upregulation of IL-8 and VEGF gene expres-
sion through an NF-nB–dependent pathway in androgen-
insensitive prostate cancer cells lines. Another group reported
that bombesin-related peptides possess immunoregulatory
activities because bombesin stimulated superoxide anion
production and IL-8 release by peripheral monocytes, en-
hancing monocyte and macrophage activities and promoting
local pulmonary defenses in chronic bronchitis [31]. These
studies further support our findings demonstrating the role of
GRP/GRP-R in angiogenesis and, potentially, in immune
modulation in neuroblastomas. Tumor invasiveness is regu-
lated by multiple factors. Recently, the coordinated expres-
sion of integrin subunits, matrix metalloproteinases (MMPs),
angiogenic genes IL-8 and PEA3, and Ets-1 transcription
factors has been detected in advanced-stage ovarian carci-
noma [32]. It will be of significance to identify whether such
mechanisms also exist in GRP-R–mediated neuroblastoma
invasiveness. Our preliminary data indicate that GRP-R
overexpression upregulates MMP-1 and MMP-3 and down-
regulates TIMP-1, a tissue inhibitor of metalloproteinase.
GRP treatment increasedMMP-2 andMMP-9 and decreased
TIMP-1 protein levels (unpublished data).
Taken together, we conclude that GRP promotes angio-
genesis in neuroblastomas, by activating the Ets1 tran-
scription factor and its downstream target IL-8, to induce
aggressive tumor behavior. Tumor vascularity correlates with
an aggressive phenotype suggesting that antiangiogenic
therapy may be a useful addition to current treatment strat-
egies for high-risk advanced-stage neuroblastomas.
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